Literature DB >> 15823441

Pharmacological therapies for obesity.

Lee M Kaplan1.   

Abstract

Pharmacological therapy for obesity is in transition. Historically,there have been few effective agents, and many have been with-drawn because of unacceptable side effects. Current options include three medications approved by the FDA for the treatment of obesity: phentermine, sibutramine and orlistat. Phentermine and sibutramine suppress appetite and promote thermogenesis,and orlistat blocks fat digestion and absorption in the gut. Several drugs approved for other indications often promote weight loss, including bupropion, metformin, topiramate and zonisamide; they have been used empirically for treatment of obesity and to counter the weight-promoting effects of other medications. Expanding knowledge of the physiological mechanisms of body weight regulation has revealed new molecular targets, and more than 150 novel agents are under active development. Because weight regulation is complex, and redundant systems protect against perceived starvation, optimal treatment of obesity will likely require combinations of therapies. The accelerating emergence of new medications will facilitate the development of such effective combinations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823441     DOI: 10.1016/j.gtc.2004.12.002

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  24 in total

1.  Cashew apple extract inhibition of fat storage and insulin resistance in the diet-induced obesity mouse model.

Authors:  Vickram Beejmohun; Cyril Mignon; Aude Mazollier; Marie Peytavy-Izard; Dominique Pallet; Manuel Dornier; Nicolas Chapal
Journal:  J Nutr Sci       Date:  2015-12-02

2.  Retinal function and histopathology in rabbits treated with Topiramate.

Authors:  S Kjellström; A Bruun; B Isaksson; T Eriksson; S Andréasson; V Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-11-18       Impact factor: 2.379

3.  Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.

Authors:  A Gursoy; M F Erdogan; M O Cin; M Cesur; N Baskal
Journal:  Eat Weight Disord       Date:  2006-12       Impact factor: 4.652

4.  Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.

Authors:  Joel Z Stengel; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-06

5.  Gastric bypass reduces fat intake and preference.

Authors:  Carel W le Roux; Marco Bueter; Nadine Theis; Malin Werling; Hutan Ashrafian; Christian Löwenstein; Thanos Athanasiou; Stephen R Bloom; Alan C Spector; Torsten Olbers; Thomas A Lutz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-07-06       Impact factor: 3.619

Review 6.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  Different gut microbiome composition in obese Guizhou minipigs between female and castrated male.

Authors:  Gang Yao; Shuguang Wu; Xianchun Zeng; Hai Zhao; Guoqi Wang; Mingfei Chen; Ning Qian
Journal:  Folia Microbiol (Praha)       Date:  2019-04-22       Impact factor: 2.099

Review 8.  Cellular bioenergetics as a target for obesity therapy.

Authors:  Yu-Hua Tseng; Aaron M Cypess; C Ronald Kahn
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

Review 9.  New treatments for nonalcoholic fatty liver disease.

Authors:  Stephen A Harrison
Journal:  Curr Gastroenterol Rep       Date:  2006-02

10.  A novel chemical uncoupler ameliorates obesity and related phenotypes in mice with diet-induced obesity by modulating energy expenditure and food intake.

Authors:  Y-Y Fu; M Zhang; N Turner; L-N Zhang; T-C Dong; M Gu; S J Leslie; J-Y Li; F-J Nan; J Li
Journal:  Diabetologia       Date:  2013-08-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.